Adult Dosing

Local treatment of vulvovaginal candidiasis (moniliasis)

Vaginal cream

• One applicatorful (5 g) of 0.4% cream intravaginally daily at bedtime for 3 consecutive days
• Alt: One applicatorful (5 g) of 0.8% cream intravaginally daily at bedtime for 3 consecutive days
• Severe or recurrent uncomplicated cases may require 7 or more days.

Vaginal suppositories

• 80 mg Intravaginally at bedtime x 3 days

Pediatric Dosing

• Safety and effectiveness has not been established

• Treatment of vulvovaginal candidiasis

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

See Supplemental Patient Information

• Anaphylaxis and toxic epidermal necrolysis may occur with terconazole therapy. Discontinue if anaphylaxis or toxic epidermal necrolysis develops
• Caution in first trimester of pregnancy
• Confirm diagnosis of vaginal candidiasis by KOH smears and or cultures
• Repeat microbiologic studies to confirm diagnosis in case of lack of response to terconazole
• Discontinue use if sensitization, irritation, fever, chills or flu-like symptoms occur
• Use cautiously if using latex/rubber contraceptive use (Suppositories)

Supplemental Patient Information

• Education about yeast infections advisable.

Pregnancy Category:C; avoid during first trimester because of absorption possibility

Breastfeeding: Safety unknown, other antifungals may be preferred, especially while nursing a newborn or a preterm infant. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 28 April 2010).

• GU: Dysmenorrhea, genitalia pain, vulvovaginal burning, vulvovaginal pruritus, vulvovaginal soreness, pelvic pain, pelvic cramps
• CNS: Headache
• GI: Abdominal pain
• MISC: Body pain, fever, chills

• Antifungals; Disrupts normal fungal cell membrane permeability, allowing leakage of cellular contents. Not active against bacteria
• 5-16% systemic absorbtion following intravaginal application
• Extensively metabolized by liver by oxidation and conjugation
• Excreted in feces (47-52%) and urine (32-56%)
• Half-life: 6.9 hrs (terconazole); 52.2 hrs (metabolite)

US Trade Name(s)

• Terazol 3
• Terazol 7

US Availability

terconazole (generic)

• CRE: 0.4% (45 g)
• CRE: 0.8% (20 g)
• SUPP: 80 mg

Terazol 3

• CRE: 0.8% (20 g)
• SUPP: 80 mg

Terazol 7

• CRE: 0.4% (45 g)

Canadian Trade Name(s)

• Terazol 3 dual pack
• Terazol 7

Canadian Availability

terconazole (generic)

• CRE: 0.4% (45 g with applicator)

Terazol 3 dual pack

• CRE: 0.8%
• OVULES: 80 mg

Terazol 7

• CRE: 0.4%

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Antimicrobials

Vaginal Agents; Anti-infectives

Infectious Disease

Vaginal Agents; Anti-infectives

Obstetrics/Gynecology

Vaginal Agents; Anti-infectives

Pricing data from www.DrugStore.com in U.S.A.

• Terazol 3 0.8 % CREA [Tube] (JANSSEN PHARMACEUTICALS)
  20 % = $51.99
  60 % = $149.98
• Terconazole 0.8 % CREA [Tube] (WATSON LABS)
  20 % = $34.99
  60 % = $94.98
• Terazol 3 80 MG SUPP [Box] (JANSSEN PHARMACEUTICALS)
  3 mg = $53.99
  9 mg = $149.98
• Terazol 7 0.4 % CREA [Tube] (JANSSEN PHARMACEUTICALS)
  45 % = $53.99
  135 % = $147.98
• Terconazole 0.4 % CREA [Tube] (WATSON LABS)
  45 % = $39.99
  135 % = $109.97

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.